Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

被引：66

作者：

Abdi, Muna H. ^{[1
]}

Beswick, Paul J. ^{[1
]}

Billinton, Andy ^{[1
]}

Chambers, Laura J. ^{[1
]}

Charlton, Andrew ^{[1
]}

Collins, Sue D. ^{[1
]}

Collis, Katharine L. ^{[1
]}

Dean, David K. ^{[1
]}

Fonfria, Elena ^{[1
]}

Gleave, Robert J. ^{[1
]}

Lejeune, Clarisse L. ^{[1
]}

Livermore, David G. ^{[1
]}

Medhurst, Stephen J. ^{[1
]}

Michel, Anton D. ^{[1
]}

Moses, Andrew P. ^{[1
]}

Page, Lee ^{[1
]}

Patel, Sadhana ^{[1
]}

Roman, Shilina A. ^{[1
]}

Senger, Stefan ^{[1
]}

Slingsby, Brian ^{[1
]}

Steadman, Jon G. A. ^{[1
]}

Stevens, Alexander J. ^{[1
]}

Walter, Daryl S. ^{[1
]}

机构：

[1] GlaxoSmithKline, Neurosci Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 17期

关键词：

P2X7; Antagonist; Pain; SAR; PAIN; HYPERALGESIA; MODEL;

D O I：

10.1016/j.bmcl.2010.07.033

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5080 / 5084

页数：5

共 27 条

[1] Ligand efficiency indices for effective drug discovery
Abad-Zapatero, Cele
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (04) : 469 - 488
[2] BENNETT GJ, 1988, PAIN, V50, P355
[3] Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor
Beswick, Paul J.
Billinton, Andy
Chambers, Laura J.
Dean, David K.
Fonfria, Elena
Gleave, Robert J.
Medhurst, Stephen J.
Michel, Anton D.
Moses, Andrew P.
Patel, Sadhana
Roman, Shilina A.
Roomans, Sue
Senger, Stefan
Stevens, Alexander J.
Walter, Daryl S.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (15) : 4653 - 4656
[4] Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation
Broom, Daniel C.
Matson, David J.
Bradshaw, Elizabeth
Buck, Marianne E.
Meade, Robin
Coombs, Susan
Matchett, Michele
Ford, Kristen K.
Yu, Weifeng
Yuan, Jun
Sun, Synthia H.
Ochoa, Ricardo
Krause, James E.
Wustrow, David J.
Cortright, Daniel N.
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) : 620 - 633
[5] EXTRACELLULAR ATP INDUCES A LARGE NONSELECTIVE CONDUCTANCE IN MACROPHAGE PLASMA-MEMBRANES
BUISMAN, HP
STEINBERG, TH
FISCHBARG, J
SILVERSTEIN, SC
VOGELZANG, SA
INCE, C
YPEY, DL
LEIJH, PCJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (21) : 7988 - 7992
[6] Chambers L. J., 2008, PCT Int. Appl, Patent No. [WO2008003697, 2008003697, WO2008003697A1]
[7] Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor
Chambers, Laura J.
Stevens, Alexander J.
Moses, Andrew P.
Michel, Anton D.
Walter, Daryl S.
Davies, David J.
Livermore, David G.
Fonfria, Elena
Demont, Emmanuel H.
Vimal, Mythily
Theobald, Pam J.
Beswick, Paul J.
Gleave, Robert J.
Roman, Shilina A.
Senger, Stefan
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (10) : 3161 - 3164
[8] Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain
Chessell, IP
Hatcher, JP
Bountra, C
Michel, AD
Hughes, JP
Green, P
Egerton, J
Murfin, M
Richardson, J
Peck, WL
Grahames, CBA
Casula, MA
Yiangou, Y
Birch, R
Anand, P
Buell, GN
[J]. PAIN, 2005, 114 (03) : 386 - 396
[9] Utility of metabolic stability screening:: comparison of in vitro and in vivo clearance
Clarke, SE
Jeffrey, P
[J]. XENOBIOTICA, 2001, 31 (8-9) : 591 - 598
[10] Tissue distribution of the P2X(7) receptor
Collo, G
Neidhart, S
Kawashima, E
KoscoVilbois, M
North, RA
Buell, G
[J]. NEUROPHARMACOLOGY, 1997, 36 (09) : 1277 - 1283

← 1 2 3 →